GSK’s RSV vaccine Arexvy got FDA approval for at-risk adults aged 50-59.

in health •  5 months ago 

image.png

The CDC's ACIP is meeting at the end of the month to discuss it.

This comes following their trial data in this age group which saw a benefit.

Pfizer for its part is also looking to expand its RSV vaccine to cover younger adults. So next RSV season, younger adults might have the opportunity to get the new RSV vaccines.

Reminder that adults 60 and older are currently able to get the RSV vaccines. And pregnant women can get a maternal RSV vaccine to protect their newborns. Likewise there is a RSV antibody injection to protect at-risk infants and toddlers.

Authors get paid when people like you upvote their post.
If you enjoyed what you read here, create your account today and start earning FREE STEEM!